EUSA CEO Says Divestment Gives It Funds, Clears Way For Cancer And Rare Disease Focus

By selling off its critical care business, EUSA Pharma gets needed funds and freedom to fully focus on oncology and rare diseases, its CEO tells Scrip.

Divestment
EUSA Pharma divestment opens way for cancer and rare disease focus • Source: Shutterstock

UK-based EUSA Pharma says it can now concentrate solely on developing its two oncology assets while hunting for new ones after agreeing to sell its critical care portfolio to Belgium-based Laboratories SERB (SERB) for an undisclosed sum.

Lee Morley, EUSA Pharma’s chief executive officer, told Scrip the deal "now lets us focus on our oncology assets without...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.